Top Tweets for #Atractib
🔄 Following up on the #ATRACTIB study results, Dr. María Gion shares new clinical insights into how this triplet regimen performs in untreated aTNBC patients.
🗣️ Interview featured in Breast Cancers Today. Dr. Gion is from Hospital Universitario Ramón y Cajal, Madrid.
Results from the phase II #ATRACTIB study, published in Nature Medicine, show promising activity for atezolizumab + paclitaxel + bevacizumab as 1L treatment in advanced TNBC, regardless of PD-L1 status.
🧵👇
📢 New publication in Nature Medicine! The phase 2 #ATRACTIB trial tested atezolizumab + paclitaxel + bevacizumab as 1L for advanced TNBC, regardless of PD-L1 status.
🕒 Median PFS: 11 months
🎯 ORR: 63%
🔗 Read the full article here 👉🏼
https://t.co/PHnxSMQCQF
#BreastCancer
Datos de seguridad 🛟, eficacia 📈y más ✅ sobre el estudio #ATRACTIB presentados durante el #SABCS23 de la voz de su 👩🔬 principal @maria_gion en https://t.co/fmscXHRmEf
La 👩⚕️@maria_gion también fue nuestra representante 🇪🇸 en @SABCSSanAntonio con el ensayo F2 #ATRACTIB que estudia en 1⃣ra línea #Atezolizumab + #Bevacizumab + #Paclitaxel en 👩con #CMTN avanzado. Explore 👁🗨 los resultados completos https://t.co/fmscXHRmEf
Exciting results of the #ATRACTIB study greatly presented by @maria_gion 😎🎉 at #SABCS2023, regardless of PD-L1 expression (!)
Exciting #SABCS23 session in the Stars at Night Ballroom on enhancing #Immunotherapy for #TNBC! Discover insights from the #ATRACTIB study, which combined atezolizumab, paclitaxel & bevacizumab for 1L advanced TNBC.
Exciting #SABCS23 session in the Stars at Night Ballroom on enhancing #Immunotherapy for #TNBC! Discover insights from the #ATRACTIB study, which combined atezolizumab, paclitaxel & bevacizumab for 1L advanced TNBC.
Una representante de 🇪🇸 en #SABCS23 es la 👩@maria_gion con el póster sobre resultados del estudio F2 #ATRACTIB 1ra línea de #atezolizumab + #bevacizumab + #paclitaxel en 🧔♀️con #cancerdemama triple negativo, pronto información en nuestra NL, suscríbete https://t.co/BYiVaX6oIr
We're still glowing from our #ASCO22 experience! Great to be in person & update the scientific community on #LUPER with @Tony_Calles & #ATRACTIB with @maria_gion. Always good to see friends & learn about the latest in oncology care. Click the link for the data we presented!
Head over to the posters to discuss some of the results of our #ATRACTIB trial with @maria_gion which is evaluating treatment for triple negative breast cancer. #ASCO22 #breastcancer #TNBC
We presented our #ATRACTIB trial at #EMSOBreast22 yesterday! This trial is evaluating first-line atezolizumab with paclitaxel and bevacizumab for advanced or metastatic TNBC and just finished recruitment! Download the poster in the link.
#breastcancer #TNBC
Our #ATRACTIB trial to evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel and bevacizumab in patients with advanced or metastatic triple-negative #breastcancer is 80% recruited and will be presented at #ESMOBreast22 next week!
#TNBC
Today is #TNBCDay, a day dedicated to raising awareness and funds for #TNBC. At MEDSIR we're dedicated to finding a treatment for these patients & have several clinical trials for TNBC. Head to our website to learn more about our #Atractib #Barbican & #Pathfinder trials!
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.5M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82M followers
Lady Gaga
@ladygaga
73.5M followers
Virat Kohli
@imvkohli
70.7M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.2M followers
X
@x
60.8M followers